ClinicalTrials.gg

Program

GSK5926371

A development code.

In GlaxoSmithKline's pipeline, Anti CD19-CD20-CD3 trispecific antibody. Its studies are mostly in Lymphoma, Non-Hodgkin · Lupus Erythematosus, Systemic, led by GlaxoSmithKline.

Furthest: phase 2, since May 19, 20262 company-led studies, 2 open or runningNext primary completion: Mar 15, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 2since May 19, 2026Jan 19, 2026Mar 15, 2028phase 1 · NCT07371468
  • Named in GlaxoSmithKline’s own pipeline as GSK5926371, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07371468 · 44 planned · Argentina, Brazil, France and more
  2. May 19, 2026Phase 2 study in Lymphoma, Non-HodgkinPhase 2 reachedNCT07607925 · 49 planned · United States, Australia, Canada and more
  3. Oct 30, 2026Primary completion moved from 2029-09-24 to 2030-01-10Date moved laterphase 2 · +4 months · NCT07607925

Ahead

  1. Mar 15, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07371468
  2. Jan 10, 2030Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07607925

TargetBeta

“Anti CD19-CD20-CD3 trispecific antibody”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07607925Lymphoma, Non-Hodgkin · United States, Australia, Canada and more2RecruitingJan 10, 203049
NCT07371468Lupus Erythematosus, Systemic · Argentina, Brazil, France and more1RecruitingMar 15, 202844

How it is read

Names in the registry

  • “GSK5926371”, 2 entries

Codes read as this program: GSK5926371.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.